The executives at Pfizer Inc. (NYSE:PFE) and Johnson & Johnson JNJ are giving each other headaches over an ad for a widely used pain reliever. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 1.91%. On last trading day company shares ended up $30.37. Analysts mean target price for the company is $34.40. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is 2.16%.
MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 30,000 shares of the company’s stock on the open market in a transaction dated Thursday, June 26th. The shares were sold at an average price of $10.51, for a total value of $315,300.00. Following the completion of the sale, the vice president now directly owns 102,286 shares in the company, valued at approximately $1,075,026. MannKind Corporation (NASDAQ:MNKD) shares fell -4.26% in last trading session and ended the day on $9.88. MNKD return on assets is -82.40%.MannKind Corporation (NASDAQ:MNKD) quarterly performance is 41.34%.
The University Of Mississippi Medical Center is taking its HIV and AIDS prevention work to the jailhouse. The hospital announced recently that Gilead Sciences Inc. (NASDAQ:GILD) a Foster City, Calif.-based biopharmaceutical company, is providing funds for a voluntary HIV testing program at the Hinds County Detention Center in Raymond. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved up 2.12% in last trading session and was closed at $87.10, while trading in range of $85.38 – $87.88. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is 15.98%.
Brinson Patrick started coverage on shares of Stemcells Inc. (NASDAQ:STEM) in a research note issued on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $7.00 price target on the stock. Brinson Patrick’s price objective would suggest a potential upside of 250.00% from the company’s current price. StemCells Inc. (NASDAQ:STEM) ended the last trading day at $2.29. Company weekly volatility is calculated as 6.99% and price to cash ratio as 4.80.StemCells Inc. (NASDAQ:STEM) showed a positive weekly performance of 8.02%.
Zogenix Inc. (NASDAQ:ZGNX) plans to submit a sNDA by October 2014 for a next-generation version of Zohydro (hydrocodone bitartrate) Extended-Release Capsules that incorporates unspecified abuse deterrent technology designed to make it more difficult to abuse via injection or snorting. If approved, the new formulation will be available in early 2015. Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is 21.65%. On last trading day company shares ended up $2.36. Analysts mean target price for the company is $4.48. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average (SMA50) is 10.34%.